Clinical Trials
26 trialsNCT01552434 2026-05-15
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05861947 2026-04-17
JIVAN
Aurigene Discovery Technologies Limited
Phase 1 Terminated
NCT05014139 2025-11-20
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Astellas Pharma Inc
Phase 1 Terminated
NCT04272034 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT06285097 2025-09-17
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT04458259 2025-08-28
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT04116320 2025-07-14
AM-003
University of Virginia
Phase 1 Terminated
NCT06630247 2025-06-25
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
Exelixis
Phase 1 Terminated
NCT05242822 2025-05-07
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
Kinnate Biopharma
Phase 1 Terminated
NCT06034860 2024-11-01
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
Phase 1 Terminated
NCT03809624 2024-10-23
PDL1x41BB
Inhibrx Biosciences, Inc
Phase 1 Terminated
NCT03518320 2024-08-27
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
Taris Biomedical LLC
Phase 1 Terminated
NCT04628780 2024-07-29
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Pfizer
Phase 1 Terminated
NCT03915405 2024-04-25
KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
Kyowa Kirin Co., Ltd.
Phase 1 Terminated
NCT04244552 2023-12-29
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Atreca, Inc.
Phase 1 Terminated
NCT04187872 2023-12-27
TORCH
University of Florida
Phase 1 Terminated
NCT05069935 2023-09-21
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT03927573 2023-07-10
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
AvenCell Therapeutics, Inc.
Phase 1 Terminated
NCT03265080 2023-02-24
NEO
Advaxis, Inc.
Phase 1 Terminated
NCT04060342 2022-08-18
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.
Phase 1 Terminated
NCT04596033 2022-07-15
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
Phase 1 Terminated
NCT04173338 2022-06-14
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
Augusta University
Phase 1 Terminated
NCT02608125 2020-12-24
A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma
Principia Biopharma, a Sanofi Company
Phase 1 Terminated
NCT03407976 2020-07-15
APPEASE
University of Utah
Phase 1 Terminated
NCT03106610 2018-05-24
Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00565227 2016-12-02
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
University of Michigan Rogel Cancer Center
Phase 1 Terminated